4 Stocks You’ll Wish You Bought on This Dip (One Is Down Over 50%)

Market Overview and Opportunities00:00:00

Introduction to buying the dip as a wealth-building strategy. Alec Green discusses the current market uptrend which is concentrated in the Magnificent 7 and hyperscalers, leaving many other stocks trading below their 50-day moving average. He highlights the midterm miracle, a historical cyclical pattern where markets average 19.5% growth in the nine months following midterms, regardless of who wins.

Diversification and Mercado Libre00:04:55

Discussion on the importance of global diversification, noting the US is only 25% of the world's economy. Alec presents Mercado Libre (MELI), known as the Amazon of Latin America, as a top buy-the-dip opportunity. He explains that despite recent margin concerns, the company dominates e-commerce in Latin America and is undervalued based on long-term growth prospects.

Novo Nordisk and GLP-1 Drugs00:10:10

Analysis of Novo Nordisk (NVO), an international pharmaceutical company known for weight-loss drugs like Wegovy. Alec notes the stock is down over the last 52 weeks due to earnings misses and competition from Eli Lilly, but trades at less than 10 times earnings with a high dividend yield. He emphasizes the massive market for obesity treatment and its secondary health benefits.

Tyler Technologies00:15:21

Review of Tyler Technologies (TYL), a software company specializing in public sector efficiency. Alec describes it as a 'sticky' business because government contracts are hard to lose once secured. He addresses the recent software sell-off driven by AI fears as overblown, noting that AI will augment rather than replace their services, and earnings remain on an uptrend.

Summit Technologies and Trading Strategy00:18:36

Presentation of Summit Technologies (SMMT), a speculative China-based biotech company with a lung cancer drug awaiting FDA approval in mid-November. Alec advises caution due to its pre-revenue status but highlights the potential for a significant spike upon approval. He concludes by explaining his trailing stop-loss strategy to protect profits and limit losses.